Michael Ezekowitz MD, PhD is exploring new options for anti-coagulation in patients with atrial fibrillation. Blood clots that can form in the hearts of atrial fibrillation patients can cause strokes. Previous research by Dr. Ezekowitz proved that the blood thinning agent warfarin (Coumidin®) can protect such patients from strokes. However, warfarin is difficult to manage clinically and not all patients can tolerate treatment with this drug. In his current work, Dr. Ezekowitz is evaluating an experimental anti-coagulation drug that may provide an important new option for patients that have difficulty with warfarin.

LIMR researchers collaborate closely with members of the Main Line Health Heart Center at Lankenau Hospital, which is a national leader in the treatment of cardiac and cardiovascular diseases, and with leading cardiologists who practice at Bryn Mawr Hospital.

LIMR Clinical Affiliate Faculty